Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 100,200
- Avg volume
- 183,514
- Day's range
- $0.01 – $0.02
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical cou...
Show more
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 888-901-0036
- Website
- https://revivethera.com
- Address
- The Canadian Venture Building, 82 Richmond Street East, Toronto, Canada
Latest news
No headlines yet.
